Thermo Fisher Scientific Inc.: Form 10-Q for the period ended Jul 1, 2017
Filed with the SEC on Aug 4, 2017 and accepted by EDGAR at Aug 4, 2017, 08:44 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-07-01. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2017-04-02 to 2017-07-01 | $2.24bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 6 months2017-01-01 to 2017-07-01 | $4.37bn | us-gaap:CostOfGoodsSold |
| Research and development | 3 months2017-04-02 to 2017-07-01 | $221.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-01-01 to 2017-07-01 | $437.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-04-02 to 2017-07-01 | $1.29bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2017-01-01 to 2017-07-01 | $2.62bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-04-02 to 2017-07-01 | $751.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-07-01 | $1.37bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-04-02 to 2017-07-01 | $133.6m | us-gaap:InterestExpense |
| Interest expense | 6 months2017-01-01 to 2017-07-01 | $269.0m | us-gaap:InterestExpense |
| Income tax | 3 months2017-04-02 to 2017-07-01 | $13.4m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-07-01 | −$35.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-02 to 2017-07-01 | $611.6m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2017-01-01 to 2017-07-01 | $1.16bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2017-04-02 to 2017-07-01 | $1.56 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-07-01 | $2.95 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-04-02 to 2017-07-01 | $1.57 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2017-01-01 to 2017-07-01 | $2.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-04-02 to 2017-07-01 | 393,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2017-01-01 to 2017-07-01 | 393,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2017-01-01 to 2017-07-01 | $1.21bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-01-01 to 2017-07-01 | $181.4m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months2017-01-01 to 2017-07-01 | $117.8m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 6 months2017-01-01 to 2017-07-01 | $750.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-07-01 | $611.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-07-01 | $7.45bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-07-01 | $46.51bn | us-gaap:Assets |
| Current liabilities | At period end2017-07-01 | $5.08bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | At period end2017-07-01 | $1.54bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2017-07-01 | $22.39bn | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2017-07-01 | 390,119,503 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000097745-17-000041. Last ingested by Listed: Nov 14, 2026, 12:05 ET. Listed shows no prices and gives no investment advice.